secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002980
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025
--------------------------------------------------------------------------------

- Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.
- Cash, equivalents and marketable securities $673.3M at March 31, sufficient to fund operations through 2027.
- Phase 3 barzolvolimab CSU studies (EMBARQ-CSU1/2) enrolling; Phase 2 EoE enrollment complete; data expected 2025.
- 76-week CSU Phase 2 data accepted for late-breaking oral presentation at EAACI June 2025.
- Bispecific CDX-622 Phase 1 in healthy volunteers enrolling; Part 1 data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184325002980/0001171843-25-002980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184325002980/f8k_050825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer